NEC and Biomy Partner to Develop and Expand AI-Based Analytical Platforms in the Digital Pathology Field

Tokyo, Japan, January 10, 2025 - NEC Corporation (NEC; TSE: 6701) and Biomy, Inc. (Biomy) have signed a Memorandum of Understanding (MoU) for a joint marketing partnership to develop and expand artificial intelligence/deep learning (AI/DL)-based analytical platforms in the field of digital pathology¹. Through this partnership, the two companies aim to promote precision medicine for cancer patients and contribute to the advancement of the healthcare industry. Precision medicine, in which more effective treatments with fewer potential side effects are selected based on each patient's unique characteristics and disease profile, is becoming increasingly prevalent. In pathology diagnostics², the use of AI/DL algorithms to analyze digital pathology images is being explored to identify pathological biomarkers³ that can stratify patients and facilitate the selection of the most patient-tailored and promising treatments and drugs. As a social value creation company focused on solving various societal issues through advanced technologies, NEC has positioned healthcare and life sciences as a core pillar of its growth strategy. With a strong foundation in image analysis and other AI technologies, NEC has a long history of providing medical information systems such as electronic medical records to healthcare institutions. Additionally, NEC has acquired a license for manufacturing and marketing Class I medical devices in Japan, demonstrating expertise in regulatory approval processes for medical devices, including AI/DL-based digital pathology systems.

Biomy, which aims to realize personalized medicine through pathological AI technology, has developed DeepPathFinder™^,4, a proprietary, cloud-based, AI/DL automated digital pathology analytical platform. This platform automatically analyzes digital pathology images to classify cell and tissue types in specific regions and offers the unique ability to detect immune cells such as lymphocytes and plasma cells⁵ from hematoxylin and eosin (H&E)-stained images⁶ only along with spatial biology features. It also quantifies characteristics related to drug efficacy and prognosis. By leveraging DeepPathFinder™, the efficiency and accuracy of analyses in the field of digital pathology can be dramatically enhanced.

This partnership integrates the cutting-edge AI technologies developed by NEC and Biomy with the primary objectives to enhance the DeepPathFinder™ platform for discovering new pathological biomarkers through AI/DL-based digital pathology image analysis, leverage data derived from pathological images, and support precision medicine and treatment planning, particularly in the field of cancer care. The resulting AI/DL-driven pathological biomarker discovery tool will then be offered to pharmaceutical/biotech companies and academia through the provision of the following: By advancing next-generation AI/DL-based pathology analysis platforms and promoting the use of the newly developed pathological biomarkers in clinical settings, NEC and Biomy aim to contribute significantly to the future of medical care and to deliver the promises of precision medicine to cancer patients.

Public link

Please use the above public link if you want to share this noodl on another website.